Amylyx sheds more light on Relyvrio’s late-stage trial failure in ALS
At this week’s American Academy of Neurology annual meeting, Amylyx provided additional data from its Phase III amyotrophic lateral sclerosis study showing the full extent of Relyvrio’s failure.